Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957721 · ClinicalTrials.gov registry record · NA
Diabetes Engagement and Activation Platform
A NA study of Type 2 Diabetes (T2D), sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT02957721: Completed NA study of Type 2 Diabetes (T2D), sponsored by Virginia Commonwealth University.
NCT02957721 is a NA study of Type 2 Diabetes (T2D) that has completed, run by Virginia Commonwealth University. The registered enrollment target is 350 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02957721, a NA study of Type 2 Diabetes (T2D), has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The following are hypothesized: 1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary care workflow to facilitate the care of patients with type 2 diabetes. 2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes. 3. The DEAP intervention will enhance patient activation and improve type 2 diabetes self management and glucose control
Primary Outcome
The A1C test is a blood test that provides information about a person's average levels of blood glucose, also called blood sugar, over the past 3 months. The A1C test is sometimes called the hemoglobin A1c, HbA1c, or glycohemoglobin test.
Conditions Studied
Interventions
- OTHER Usual Care
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-11-05 |
| Phase | NA |
What the finished NCT02957721 record still lists
NCT02957721 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Type 2 Diabetes (T2D) appearing as the primary indexed condition, and to 1 intervention - of which Usual Care is the first listed.
NCT02957721 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02957721 about?
NCT02957721 is a clinical study titled "Diabetes Engagement and Activation Platform". The following are hypothesized: 1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary care workflow to facilitate the care of patients with type 2 diabetes. 2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes. 3. The DEAP inte...
What is the current status of trial NCT02957721?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2017-11-01. Estimated completion is 2018-11-05.
What conditions does trial NCT02957721 study?
This clinical trial studies the following conditions: Type 2 Diabetes (T2D).
What interventions are being tested in trial NCT02957721?
The interventions under investigation include: Usual Care (OTHER).
Who is sponsoring clinical trial NCT02957721?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02957721 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02957721's enrollment target sits among peer trials
350 292nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI